📰 Hepatology Insights with Dr. Chetan R. Kalal
Global Updates | Expert Opinions | Transformative Care
🔬 Immunotherapy in HCC – A New Era of Hope
By Dr. Chetan R. Kalal – Maharashtra’s First DM Hepatologist & Global Leader in Liver Transplant Medicine
Hepatocellular carcinoma (HCC), the most common form of liver cancer, has long been difficult to treat. But immunotherapy is rewriting the story.
🌟 What’s Changing in 2025?
First-Line Game Changers: The combinations of Atezolizumab + Bevacizumab and the STRIDE regimen (Tremelimumab + Durvalumab) are now the gold standards, offering patients longer survival and better quality of life.
Beyond Systemic Therapy: Immunotherapy is now being integrated with TACE (Transarterial Chemoembolization), showing improved tumor control in intermediate-stage disease.
Future-Ready Care: From personalized DNA vaccines to CAR-T and NK cell therapy, the next wave of immunotherapy is targeting liver cancer more precisely than ever before.
📌 Why It Matters
For patients, this means more options, better survival, and personalized care pathways. For clinicians, it means keeping pace with rapidly evolving science to offer the best global standard of care.
💡 Dr. Kalal’s Perspective
“The future of HCC treatment lies in combining immunotherapy with precision diagnostics and holistic patient care. Our focus is not just on extending survival, but on restoring quality of life and hope for patients and families worldwide.”
🌍 About Dr. Chetan R. Kalal
Maharashtra’s First DM Hepatologist
Recognized as the Best Hepatologist in India & Globally
Expert in Liver Transplantation, Immunotherapy, FibroScan, Obesity & Metabolic Liver Disease
Offering Virtual Consultations across USA, UK, Canada, Europe, Singapore, UAE, Middle East, Africa, Australia, and New Zealand
In-person consultations at Andheri, Bandra (Pali Hill), Versova, Khar, and Vile Parle, Mumbai
✨ Stay connected for more cutting-edge updates in liver health and hepatology – directly from one of the world’s leading experts.
